½ÃÀ庸°í¼­
»óǰÄÚµå
1269673

¼¼°èÀÇ ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : ¾à¹° Ŭ·¡½ºº°, ŸÀÔº°, À¯Åë ä³Îº°, Áö¿ªº° ºÐ¼®(2022-2029³â)

Global Autism Spectrum Disorders Treatment Market Size Study & forecast, by Drug Class by Type, by Distribution Channel and Regional Analysis, 2022-2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ¼¼°è ½ÃÀåÀº 2021³â¿¡ ¾à 18¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ°í, ¿¹Ãø±â°£ 2022-2029³â¿¡´Â 7.4% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD)Àº »çȸÀû »óÈ£ÀÛ¿ë, Ä¿¹Â´ÏÄÉÀ̼Ç, Çൿ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ½Å°æ ¹ß´Þ Àå¾Ö Áß ÇϳªÀÔ´Ï´Ù. Áõ»ó°ú ÁßÁõµµ°¡ °³Àο¡ µû¶ó Å©°Ô ´Ù¸£±â ¶§¹®¿¡ ½ºÆåÆ®·³ Àå¾Ö¶ó°íÇÕ´Ï´Ù. ASD´Â ÀϹÝÀûÀ¸·Î À¯¾Æ±â¿¡ Áø´ÜµÇÁö¸¸, »îÀÇ ÈĹÝÀÌ µÉ ¶§±îÁö ¹ß°ßµÇÁö ¾ÊÀ» ¼öµµ ÀÖ½À´Ï´Ù. ASDÀÇ ÀϹÝÀûÀÎ Áõ»óÀ¸·Î´Â »çȸÀû »óÈ£ÀÛ¿ë°ú ÀÇ»ç¼ÒÅëÀÇ ¾î·Á¿ò, ¹Ýº¹Àû Çൿ, ƯÁ¤ °ü½É°ú ÁÖÁ¦¿¡ °­ÇÏ°Ô ÁýÁßÇÏ´Â µîÀÌ ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¼¼°è ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) ºÎ´ã Áõ°¡, ASD °ü·Ã ÀÇ½Ä Áõ°¡, ÅõÀÚ °Ç¼ö Áõ°¡, ´Ù¾çÇÑ Àç´Ü ¼³¸³ ¹× °¢±¹ ÀÚÆóÁõ °è¹ß À» À§ÇÑ ´Ù¾çÇÑ ÀÚ±ÝÀÇ Àΰ¡¿Í °°Àº Á¤ºÎÀÇ ³ë·ÂÀÇ Áõ°¡´Â ¿¹Ãø±â°£ µ¿¾È ½ÃÀå¿¡ À¯¸®ÇÑ ¼ö¿ä¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

±×·¯³ª ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD)ÀÇ À¯º´·ü Áõ°¡¿Í ASD Áø´Ü·ü »ó½ÂÀ¸·Î À̾îÁý´Ï´Ù. ¿¹¸¦ µé¾î, ¼¼°èº¸°Ç±â±¸(WHO)´Â 2022³â 3¿ù¿¡ ¼¼°è ¾î¸°ÀÌ 100¸í Áß 1¸íÀÌ ÀÚÆó½ºÆåÆ®·³Àå¾ÖÀ» ¾Î°í ÀÖ´Ù°í ÃßÁ¤ÇÕ´Ï´Ù. ASD¸¦ ÀÌÇØÇÏ°í °ü¸®Çϱâ À§Çؼ­´Â Á¶±â ¹ß°ßÀÌ ÇʼöÀûÀÔ´Ï´Ù. ¸¹Àº Á¶»ç¿¡ µû¸£¸é Áø´ÜÀÇ Æò±Õ ¿¬·ÉÀº 3¼¼¿¡¼­ 6¼¼·Î »çȸ °æÁ¦Àû ¼öÁذú ¹ÎÁ·Àû ¹è°æ¿¡ µû¶ó »ó´çÇÑ Â÷À̰¡ ÀÖ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¶ÇÇÑ ÀÚÆó½ºÆåÆ®·³Àå¾Ö Ä¡·á¹ýÀÇ Áøº¸¸¦ À§ÇÑ R&D Ȱµ¿ Ȱ¼ºÈ­, ½ÅÁ¦Ç° °³¹ß ¹× Á¦Ç° ½ÂÀÎÀº ¿¹Ãø±â°£ µ¿¾È ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ÀÚÆó½ºÆåÆ®·³Àå¾ÖÀÇ Ä¡·á¿Í Áø´Ü¿¡ µå´Â ºñ¿ëÀÌ ³ô°í Á¦Ç° ½ÂÀΰú °ü·ÃµÈ ±ÔÁ¦°¡ ¾ö°ÝÇϱ⠶§¹®¿¡ 2022³âºÎÅÍ 2029³âÀÇ ¿¹Ãø±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.

ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ¼¼°è ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, Áß³²¹Ì ¹× ±âŸ Áö¿ªÀÔ´Ï´Ù. ºÏ¹Ì´Â ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç, ¹Ì±¹¿¡¼­ÀÇ ÀÚÆóÁõ ÁúȯÀÇ À¯º´·üÀÇ Áõ°¡, Ä¡·á¹ýÀÇ º¸±Þ¡¤Ä§Åõ¿¡ ÀÇÇØ ½ÃÀå Á¡À¯À²¿¡¼­ ¼¼°èÀÇ ÁÖ¿ä Áö¿ªÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹Ý¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀº È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º´¿ø°ú °°Àº ¼³ºñ°¡ °®Ãß¾îÁø ÀÇ·á±â°ü¿¡ ´ëÇÑ ¿ä±¸¸¦ ÃæÁ·½Ã۱â À§ÇÑ ÀÇ·á ÀÎÇÁ¶óÀÇ Á¤ºñ´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀå¿¡ À¯¸®ÇÑ ¼ºÀå Àü¸ÁÀ» °¡Á®¿Ã °ÍÀ¸·Î »ý°¢µË´Ï´Ù.

ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â µ¿¾È ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇÏ°í ¾ÕÀ¸·Î ¼ö³â°£ÀÇ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡ »ê¾÷ÀÇ ÁúÀû ¹× ¾çÀû Ãø¸éÀ» Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦ µî Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï »óȲ°ú Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀûÀÎ ±âȸµµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇöȲ
  • ¼¼°è¡¤ºÎ¹®º° ½ÃÀå ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
    • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀå, Áö¿ªº°, 2019-2029³â
    • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀå, ¾à¹° Ŭ·¡½ºº°, 2019-2029³â
    • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀå, ŸÀÔº°, 2019-2029³â
    • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀå, À¯Åë ä³Îº°, 2019-2029³â
  • ÁÖ¿ä µ¿Çâ
  • Á¶»ç ¹æ¹ý
  • Á¶»çÀÇ °¡Á¤

Á¦2Àå ¼¼°èÀÇ ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • Á¶»ç ´ë»ó ¹üÀ§
    • »ê¾÷ÀÇ ÁøÈ­
  • º» Á¶»çÀÇ ´ë»óÀÌ µÈ ÇØ
  • ȯÀ² º¯È¯À²

Á¦3Àå ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ¼¼°è ½ÃÀå ¿ªÇÐ

  • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀåÀÇ ¿µÇ⠺м®(2019-2029³â)
    • ½ÃÀå ÃËÁø¿äÀÎ
      • ¼¼°èÀûÀ¸·Î Áõ°¡ÇÏ´Â ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD)ÀÇ ºÎ´ã Áõ°¡
      • ASD¿¡ ´ëÇÑ ÀÎÁöµµ Çâ»ó°ú ÅõÀÚ °Ç¼ö Áõ°¡
    • ½ÃÀåÀÇ °úÁ¦
      • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á¡¤Áø´Ü¿¡ °É¸®´Â °í¾×ÀÇ ºñ¿ë
      • Á¦Ç° ½ÂÀΰú °ü·ÃµÈ ¾ö°ÝÇÑ ±ÔÁ¦
    • ½ÃÀå ±âȸ
      • ÀÚÆó½ºÆåÆ®·³Àå¾Ö Ä¡·á¹ýÀÇ Áøº¸¸¦ ÇâÇÑ ¿¬±¸ °³¹ß Ȱµ¿ Ȱ¹ßÈ­

Á¦4Àå ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ¼¼°è ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's 5 Force ¸ðµ¨
    • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷ °£ÀÇ Àû´ë °ü°è
  • Porter's 5 Force ¸ðµ¨¿¡ ´ëÇÑ ¹Ì·¡Àû Á¢±Ù(2019-2029³â)
  • PEST ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • ¾÷°è °ü°èÀÚ Àü¸Á
  • ¾Ö³Î¸®½ºÆ®ÀÇ ±Ç°í¿Í °á·Ð

Á¦5Àå À§Çè Æò°¡: COVID-19ÀÇ ¿µÇâ

  • COVID-19°¡ ¾÷°è¿¡ ¹ÌÄ¡´Â ÀüüÀûÀÎ ¿µÇâ¿¡ ´ëÇÑ Æò°¡
  • COVID-19 ÀÌÀü°ú COVID-19 ÀÌÈÄÀÇ ½ÃÀå ½Ã³ª¸®¿À

Á¦6Àå ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ¼¼°è ½ÃÀå : ¾à¹° Ŭ·¡½ºº°

  • ½ÃÀå ÇöȲ
  • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ¼¼°è ½ÃÀå : ¾à¹° Ŭ·¡½ºº°, ½ÇÀû-ÀáÀç·Â ºÐ¼®
  • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ¼¼°è ½ÃÀå ¾à¹° Ŭ·¡½ºº° ÃßÁ¤¡¤¿¹Ãø 2019-2029
  • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • Ç×Á¤½Åº´¾à
    • SSRI/Ç׿ì¿ïÁ¦
    • °¢¼ºÁ¦
    • ±âŸ

Á¦7Àå ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ¼¼°è ½ÃÀå : ŸÀÔº°

  • ½ÃÀå ÇöȲ
  • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ¼¼°è ½ÃÀå : ŸÀÔº°, ½ÇÀû-ÀáÀçÀû ºÐ¼®
  • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ¼¼°è ½ÃÀå ŸÀÔº° ÃßÁ¤¡¤¿¹Ãø 2019-2029
  • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ÀÚÆóÁõ
    • ¾Æ½ºÆÛ°Å ÁõÈıº
    • ±âŸ ŸÀÔ

Á¦8Àå ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ¼¼°è ½ÃÀå : À¯Åë ä³Îº°

  • ½ÃÀå ÇöȲ
  • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ¼¼°è ½ÃÀå : À¯Åë ä³Îº°, ½ÇÀû-ÀáÀç·Â ºÐ¼®
  • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ¼¼°è ½ÃÀå À¯Åë ä³Îº° ÃßÁ¤¡¤¿¹Ãø 2019-2029
  • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • º´¿ø³» ¾à±¹
    • ¾à±¹¡¤Á¶Á¦ ¾à±¹
    • ¿Â¶óÀÎ ¾à±¹

Á¦9Àå ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ¼¼°è ½ÃÀå : Áö¿ªº° ºÐ¼®

  • ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀå, Áö¿ªº° ½ÃÀå ÇöȲ
  • ºÏ¹Ì
    • ¹Ì±¹
      • ¾àÁ¦ Ŭ·¡½ºº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
      • ŸÀÔº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
      • À¯Åë ä³Îº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
    • ij³ª´Ù
  • À¯·´ ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀå ÇöȲ
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀå ÇöȲ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÀÚÆó½ºÆåÆ®·³Àå¾Ö(ASD) Ä¡·á ½ÃÀå ÇöȲ
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • ¼¼°èÀÇ ±âŸ Áö¿ª

Á¦10Àå °æÀï Á¤º¸

  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Curemark, LLC(Rye, US)
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍÀÇ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì¸¸)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù µ¿Çâ
    • Alembic Pharmaceuticals Limited(Vadodara, India)
    • Yamo Pharmaceuticals(New York, US)
    • PaxMedica, Inc.(Woodcliff Lake, US)
    • F. Hoffmann-La Roche Ltd(Basel, Switzerland)
    • Aurobindo Pharma Ltd.(Hyderabad, India)
    • Otsuka Holdings Co. Ltd.(Tokyo, Japan)
    • Janssen Pharmaceuticals, Inc.(Titusville, New Jersey)
    • Teva Pharmaceutical Industries Ltd.(Tel Aviv, Israel)
    • H. Lundbeck A/S(Copenhagen, Denmark)

Á¦11Àå Á¶»ç ÇÁ·Î¼¼½º

  • Á¶»ç ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»çÀÇ Æ¯Â¡
  • Á¶»çÀÇ °¡Á¤
ksm 23.05.25

Global Autism Spectrum Disorders Treatment Market is valued at approximately USD 1.85 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 7.4% over the forecast period 2022-2029. Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder that affects social interaction, communication, and behavior. It is called a spectrum disorder because the symptoms and severity can vary widely among individuals. ASD is typically diagnosed in early childhood, but sometimes it is not identified until later in life. Some common symptoms of ASD include difficulties with social interactions and communication, repetitive behaviors, and a strong focus on specific interests or topics. The key factor supporting the market growth is the rising burden of autism spectrum disorder (ASD) globally, growing awareness pertaining to ASD and rising number of investments, and the growing number of government initiatives such as forming various foundations and sanctioning different funding for the awareness of autism in various countries is anticipated to create the lucrative demand for the market during the forecast period.

However, Autism Spectrum Disorders Treatment Market Growth is driven by the rising prevalence of autism spectrum disorder (ASD) and the rising diagnostic rate of ASD. For instance, the World Health Organization (WHO) estimates that in March 2022, one in 100 children globally will have autism spectrum disorder. Early detection of ASD is essential to comprehending and managing the condition. According to numerous research, the average age of diagnosis is between 3 and 6 years old, with considerable variations depending on the socioeconomic level and ethnic origin. Additionally, rising R&D activity for advancements in autism spectrum disorder treatment, and new product development and product approvals are anticipated to create a lucrative opportunity for the market during the forecast period. However, the high cost of autism spectrum disorder treatment and diagnosis and stringent regulations pertaining to product approval stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Autism Spectrum Disorders Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the presence of key market players, the growing prevalence of autism disorder across the U.S., coupled with the growing adoption and uptake of therapies. Whereas, Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period, owing to factors such as rising demand for effective treatment. The development of healthcare infrastructure to fulfil the need for well-equipped healthcare institutions such as hospitals would create lucrative growth prospects for the Autism Spectrum Disorders Treatment market across the Asia Pacific region.

Major market player included in this report are:

  • Curemark, LLC (Rye, U.S.)
  • Alembic Pharmaceuticals Limited (Vadodara, India)
  • Yamo Pharmaceuticals (New York, U.S.)
  • PaxMedica, Inc. (Woodcliff Lake, U.S.)
  • F. Hoffmann-La Roche Ltd (Basel, Switzerland)
  • Aurobindo Pharma Ltd. (Hyderabad, India)
  • Otsuka Holdings Co. Ltd. (Tokyo, Japan)
  • Janssen Pharmaceuticals, Inc. (Titusville, New Jersey)
  • Teva Pharmaceutical Industries Ltd. (Tel Aviv, Israel)
  • H. Lundbeck A/S (Copenhagen, Denmark)

Recent Developments in the Market:

  • In Oct. 2021, Axial Therapeutics reported that the FDA approved the company's Investigational New Drug (IND) application for its lead product, AB-2004, a molecular therapy that is being investigated for the treatment of irritability associated with ASD.

Global Autism Spectrum Disorders Treatment Market Report Scope:

  • Historical Data 2019-2020-2021
  • Base Year for Estimation 2021
  • Forecast period 2022-2029
  • Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered Drug Class, Type, Distribution Channel, Region
  • Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Drug Class:

  • Antipsychotic Drugs
  • SSRIs/Antidepressants
  • Stimulants
  • Other Drug Classes

By Type:

  • Autistic Disorder
  • Asperger's Syndrome
  • Other Types

By Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Autism Spectrum Disorders Treatment Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Autism Spectrum Disorders Treatment Market, by Drug Class, 2019-2029 (USD Billion)
    • 1.2.3. Autism Spectrum Disorders Treatment Market, by Type, 2019-2029 (USD Billion)
    • 1.2.4. Autism Spectrum Disorders Treatment Market, by Distribution Channel, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Autism Spectrum Disorders Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Autism Spectrum Disorders Treatment Market Dynamics

  • 3.1. Autism Spectrum Disorders Treatment Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising burden of autism spectrum disorder (ASD) globally
      • 3.1.1.2. Growing awareness pertaining to ASD and rising number of investments
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost of autism spectrum disorder treatment and diagnosis
      • 3.1.2.2. Stringent regulations pertaining to product approval
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising R&D activity for advancements in autism spectrum disorder treatment

Chapter 4. Global Autism Spectrum Disorders Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Autism Spectrum Disorders Treatment Market, by Drug Class

  • 6.1. Market Snapshot
  • 6.2. Global Autism Spectrum Disorders Treatment Market by Drug Class, Performance - Potential Analysis
  • 6.3. Global Autism Spectrum Disorders Treatment Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
  • 6.4. Autism Spectrum Disorders Treatment Market, Sub Segment Analysis
    • 6.4.1. Antipsychotic Drugs
    • 6.4.2. SSRIs/Antidepressants
    • 6.4.3. Stimulants
    • 6.4.4. Other Drug Classes

Chapter 7. Global Autism Spectrum Disorders Treatment Market, by Type

  • 7.1. Market Snapshot
  • 7.2. Global Autism Spectrum Disorders Treatment Market by Type, Performance - Potential Analysis
  • 7.3. Global Autism Spectrum Disorders Treatment Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
  • 7.4. Autism Spectrum Disorders Treatment Market, Sub Segment Analysis
    • 7.4.1. Autistic Disorder
    • 7.4.2. Asperger's Syndrome
    • 7.4.3. Other Types

Chapter 8. Global Autism Spectrum Disorders Treatment Market, by Distribution Channel

  • 8.1. Market Snapshot
  • 8.2. Global Autism Spectrum Disorders Treatment Market by Distribution Channel, Performance - Potential Analysis
  • 8.3. Global Autism Spectrum Disorders Treatment Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
  • 8.4. Autism Spectrum Disorders Treatment Market, Sub Segment Analysis
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores and Retail Pharmacies
    • 8.4.3. Online Pharmacies

Chapter 9. Global Autism Spectrum Disorders Treatment Market, Regional Analysis

  • 9.1. Autism Spectrum Disorders Treatment Market, Regional Market Snapshot
  • 9.2. North America Autism Spectrum Disorders Treatment Market
    • 9.2.1. U.S. Autism Spectrum Disorders Treatment Market
      • 9.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Type breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Autism Spectrum Disorders Treatment Market
  • 9.3. Europe Autism Spectrum Disorders Treatment Market Snapshot
    • 9.3.1. U.K. Autism Spectrum Disorders Treatment Market
    • 9.3.2. Germany Autism Spectrum Disorders Treatment Market
    • 9.3.3. France Autism Spectrum Disorders Treatment Market
    • 9.3.4. Spain Autism Spectrum Disorders Treatment Market
    • 9.3.5. Italy Autism Spectrum Disorders Treatment Market
    • 9.3.6. Rest of Europe Autism Spectrum Disorders Treatment Market
  • 9.4. Asia-Pacific Autism Spectrum Disorders Treatment Market Snapshot
    • 9.4.1. China Autism Spectrum Disorders Treatment Market
    • 9.4.2. India Autism Spectrum Disorders Treatment Market
    • 9.4.3. Japan Autism Spectrum Disorders Treatment Market
    • 9.4.4. Australia Autism Spectrum Disorders Treatment Market
    • 9.4.5. South Korea Autism Spectrum Disorders Treatment Market
    • 9.4.6. Rest of Asia Pacific Autism Spectrum Disorders Treatment Market
  • 9.5. Latin America Autism Spectrum Disorders Treatment Market Snapshot
    • 9.5.1. Brazil Autism Spectrum Disorders Treatment Market
    • 9.5.2. Mexico Autism Spectrum Disorders Treatment Market
    • 9.5.3. Rest of Latin America Autism Spectrum Disorders Treatment Market
  • 9.6. Rest of The World Autism Spectrum Disorders Treatment Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Curemark, LLC (Rye, U.S.)
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Alembic Pharmaceuticals Limited (Vadodara, India)
    • 10.2.3. Yamo Pharmaceuticals (New York, U.S.)
    • 10.2.4. PaxMedica, Inc. (Woodcliff Lake, U.S.)
    • 10.2.5. F. Hoffmann-La Roche Ltd (Basel, Switzerland)
    • 10.2.6. Aurobindo Pharma Ltd. (Hyderabad, India)
    • 10.2.7. Otsuka Holdings Co. Ltd. (Tokyo, Japan)
    • 10.2.8. Janssen Pharmaceuticals, Inc. (Titusville, New Jersey)
    • 10.2.9. Teva Pharmaceutical Industries Ltd. (Tel Aviv, Israel)
    • 10.2.10. H. Lundbeck A/S (Copenhagen, Denmark)

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦